



CODEN [USA]: IAJPBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**<http://doi.org/10.5281/zenodo.3550977>Available online at: <http://www.iajps.com>

Research Article

**ANALYSIS OF FACTORS INFLUENCING THE LIVER
STIFFNESS MEASUREMENT (LSM) DETECTED BY
FIBROSCAN IN CHRONIC HBV INFECTORS**Ayesha Khalid¹, Komal Ayaz², Asma Nayab²¹Doctors Hospital & Medical Center, Lahore²Isfandyar Bukhari District Hospital, Attock**Abstract:**

Objectives of the study: The basic aim of the study is to find the factors influencing the liver stiffness measurement (LSM) detected by Fibroscan in chronic HBV infectors. **Material and methods:** This cross sectional study was conducted at Doctors Hospital, Lahore during December 2018 to July 2019. The data was collected from both genders and the sample size was 50. **Results:** All the studies explains patients with chronic infection of Hepatitis, the progress and treatment depends upon the staging of the liver fibrosis. The staging of liver fibrosis is also important in determining and designing the drug combination and treatment. The chronic viral infections, as that in hepatitis, also proceed with elevation in ALT levels in the body and have contribution in the progression of fibrosis. **Conclusion:** In these patients, liver stiffness measurement (LSM) values may be limited by elevated ALT, and the LSM cutoff values for each disease stage vary from study to study due to differences in hepatic fibrosis etiology and differences in populations.

Corresponding author:

Ayesha Khalid,

Doctors Hospital & Medical Center, Lahore

QR code



Please cite this article in press Ayesha Khalid et al., *Analysis Of Factors Influencing The Liver Stiffness Measurement (LSM) Detected By Fibroscan In Chronic HBV Infectors.*, Indo Am. J. P. Sci, 2019; 06(11).

INTRODUCTION:

Liver biopsy has been considered the most important thing for the assessment of liver fibrosis. There are many rare complications which are associated with liver biopsy. Pain and hypotension are the most common complication with patients. Transient elastography has been evaluated extensively as a non-invasive tool to assess liver fibrosis¹. FibroScan is a non-invasive instrument to detect hepatic fibrosis, which is based on the technology of the elastic imaging of ultrasound. The liver solidity, which reflects the fibrosis intensity of the liver, can be evaluated by detecting the instant elasticity of the liver². Liver stiffness was measured by transient elastography using FibroScan. Recently, transient elastography has become available as a new method in the non-invasive treatment of liver fibrosis. Even though earlier studies had been performed on patients with chronic hepatitis C, more recent studies have shown transient elastography to be similar in accuracy in patients with chronic hepatitis B³. Initial studies have shown that liver stiffness measurement with transient elastography correlated well with underlying liver fibrosis, with good diagnostic performance. Most of these studies have been performed on patients who suffer from hepatitis C due to less available of data on chronic hepatitis B⁴.

The main aim of this research is to present a review of various factors that influence the measurement of Liver Stiffness Measurement (LSM) by Fibroscan in patients with HBV chronic infection. Some of the important factors include age, gender, albumin, liver inflammation represented by alanine transaminase (ALT), aspartate transaminase (AT), total bilirubin (TBIL) level, HBV replication (HBV DNA loads), portal vein pressure (portal vessel diameter, PVD), splenic thickness (SPT) and body mass index (BMI) and GGT⁵⁻⁷.

Objectives of the study

The basic aim of the study is to find the factors influencing the liver stiffness measurement (LSM) detected by Fibroscan in chronic HBV infectors.

MATERIAL AND METHODS:

This cross sectional study was conducted at Doctors Hospital, Lahore during December 2018 to July 2019. The data was collected from both genders and the sample size was 50.

Data Extraction

Some pre-specified factors to undergo the analysis included age, gender of the patient, albumin levels, liver inflammation represented by alanine transaminase (ALT), aspartate transaminase (AT), total bilirubin (TBIL) level, HBV replication (HBV DNA loads), portal vein pressure (portal vessel diameter, PVD), splenic thickness (SPT) and body mass index (BMI) and GGT (gamma glutamyl transpeptidase). The other variables that were taken into account included liver fibrosis (or liver stiffness scan) using fibroscan and patients with chronic HBV infection. Patients with liver diseases other than these reasons were excluded from the study.

Data Analysis and Synthesis

The data was analyzed using SPSS version 17.0 for SE and SD.

RESULTS:

All the studies is explained in the table 01. The table 01 explains patients with chronic infection of Hepatitis, the progress and treatment depends upon the staging of the liver fibrosis. The staging of liver fibrosis is also important in determining and designing the drug combination and treatment. The chronic viral infections, as that in hepatitis, also proceed with elevation in ALT levels in the body and have contribution in the progression of fibrosis. Therefore in treating HBV infection, designing the antiviral therapy depends on staging of fibrosis. All the studies showed that liver fibrosis and LSM were higher in CHB infected patients with elevated levels of ALT. And there was a positive correlation between LSM, ALT and male gender among all the patients with HBV infection.

Table 01: analysis of liver stiffness in chronic HBV infection

Liver Stiffness Measurement (LSM) kPa	Hepatitis B antigen (HBeAg)	% stage II	% stage III	% stage IV	ALT (IU/L)	Mean BMI (kg/m ²)
6.6 (1.5–75.0)	-	-	-	-	33 (8–962)	-
16.8 (6.9–47.2)	-	-	-	-	1464	-
11.9 ± 8.7	-	60 (30.2)	37 (18.6)	99 (49.7)	114.4 ± 160.1	23.6 ± 3.1
12.9 ± 8.6	-	23.9	14.6	23	40.6 ± 17.2	-
17.4 ± 6.2	103/253 (41%)	92 patients with F ≥ 2	-	46 patients with cirrhosis	80 ± 154 (Normal ALT and transaminases).	-
7.7	408 (36.1)	-	-	-	38.8 ± 27.2	-
9.9 ± 7.2	85 (48.6%)	-	0.95 (95% confidence interval, 0.91–0.98)	0.98 (0.96–0.99)	40.1 ± 18.6	-
21.7 ± 11.5	-	73.7±149.1		54.7±45.4	64.2 ± 97.25	-
12.9 (4.4–57.1)	-	97 (75.8)	18 (14.1)	110 (85.9)	44.46 ± 21.6	24.06 ± 2.9

DISCUSSION:

Transient elastography has been evaluated extensively as a non-invasive tool to assess liver fibrosis. In a systemic review of published studies, liver stiffness measurement (LSM) by transient elastography has high sensitivity and specificity to detect histological liver cirrhosis⁸. The liver stiffness was expressed in kilo Pascal (kPa). Patients with elevated ALT levels tend to have higher LSM than those with normal ALT levels at the same stage of liver fibrosis. Patients with elevated serum ALT levels had higher LSM values despite having the same degree of liver fibrosis. FibroScan is a non-invasive instrument to detect hepatic fibrosis, which is based on the technology of the elastic imaging of ultrasound⁹⁻¹⁰.

CONCLUSION:

In these patients, liver stiffness measurement (LSM) values may be limited by elevated ALT, and the LSM cutoff values for each disease stage vary from study to study due to differences in hepatic fibrosis etiology and differences in populations.

REFERENCES:

- Du, D., Zhu, X., Kuno, A., Matsuda, A., Tsuruno, C., Yu, D., Narimatsu, H. (2012). Comparison of LecT-Hepa and FibroScan for assessment of liver fibrosis in hepatitis B virus infected patients with different ALT levels. *Clinica chimica acta; international journal of clinical chemistry*, 413(21-22), 1796–9. doi:10.1016/j.cca.2012.07.005
- Fung, J., et al. (2008). "Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis." *LIV Liver International* 28(10): 1408-1416.
- Fung, J., Lai, C.-L., But, D., Hsu, A., Seto, W.-K., Cheng, C., Yuen, M.-F. (2010). Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B. *Hepatology international*, 4(4), 716–22. doi:10.1007/s12072-010-9189-z
- Göbel, T., et al., (2011). "High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe." *JMV Journal of Medical Virology* 83(6): 968-973.

5. Hsu, C.-W., Liang, K.-H., Huang, S.-F., Tsao, K.-C., & Yeh, C.-T. (2013). Development of a non-invasive fibrosis test for chronic hepatitis B patients and comparison with other unpatented scores. *BMC research notes*, 6, 212. doi: 10.1186/1756-0500-6-212.
6. Jin, W., Lin, Z., Xin, Y., Jiang, X., Dong, Q., & Xuan, S. (2012). Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. *BMC gastroenterology*, 12, 14. doi:10.1186/1471-230X-12-14
7. Jung, K. S., Kim, S. U., Ahn, S. H., Park, Y. N., Kim, D. Y., Park, J. Y., ... Han, K.-H. (2011). Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). *Hepatology* (Baltimore, Md.), 53(3), 885–94. doi:10.1002/hep.24121
8. Kim BK, Kim HS, Park JY, Kim DY, Ahn SH, et al. (2012) Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. *PLoS ONE* 7(7): e41964. doi:10.1371/journal.pone.0041964
9. Kim, D. Y., Kim, S. U., Ahn, S. H., Park, J. Y., Lee, J. M., Park, Y. N., ... Han, K.-H. (2009). Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. *Digestive diseases and sciences*, 54(8), 1758–63. doi:10.1007/s10620-008-0541-2
10. Kim, S U, Seo, Y. S., Cheong, J. Y., Kim, M. Y., Kim, J. K., Um, S. H., Ahn, S. H. (2010). Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B. *Alimentary pharmacology & therapeutics*, 32(3), 498–505.